Compare iShares MSCI Canada (TSX) (EWC) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Canada (TSX) vs TG Therapeutics Inc — how do they compare? iShares MSCI Canada (TSX) trades at $59.03 (market cap $6.99B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: TG Therapeutics Inc is the larger of the two by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, iShares MSCI Canada (TSX) nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Canada (TSX) for 56 Days and TG Therapeutics Inc for 16 Days on average.
| EWC | TGTX | |
|---|---|---|
Market Cap | $6.99B | $8.16B |
Volume | 1,625,847 | 1,735,121 |
Sector | Broad Market / Factor | Health |
52-Week High | $62.64 | $59.06 |
52-Week Low | $49.72 | $26.94 |
Typical Hold Time | 56 Days | 16 Days |
Enterprise Value | — | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWC trades at $58.32, up 0.66% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. Key support is at $58, with resistance at $59. Financial ratios are unavailable, limiting fundamental clarity. Recent news highlights trade tensions with the U.S. and Canada's pursuit of EU associate membership, creating uncertainty.
The outlook is clouded by geopolitical risks and lack of financial data. Upside depends on resolving trade disputes, but downside risks from U.S. tariff threats and economic softening in Canada persist. Investors need updated earnings and valuation metrics to assess true potential amid volatile conditions.
TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.
The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI Canada (TSX)
EWC is a country-specific ETF that tracks the performance of the Canadian equity market. It provides exposure to large and mid-sized companies in Canada, with heavy concentrations in financials and energy, including Royal Bank of Canada, Shopify, and Enbridge.
Read more on EWC →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
